Systematic Review

Direct-Acting Antivirals for HCV Treatment in Decompensated Liver Cirrhosis Patients: A Systematic Review and Meta-Analysis

JiHyun An 1,†, Dong Ah Park 2,†, Min Jung Ko 2, Sang Bong Ahn 3, Jeong-Ju Yoo 4, Dae Won Jun 5,*, and Sun Young Yim 6,*

1 Gastroenterology and Hepatology, Hanyang University College of Medicine, Guri 04763, Korea
2 Division of Healthcare Technology Assessment Research, National Evidence-Based Healthcare Collaborating Agency (NECA), Seoul 04933, Korea
3 Department of Internal Medicine, Nowon Eulji Medical Center, Eulji University College of Medicine, Seoul 01830, Korea
4 Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Bucheon 14584, Korea
5 Department of Internal Medicine, Hanyang University College of Medicine, Seoul 04763, Korea
6 Department of Internal Medicine, Korea University College of Medicine, Seoul 02841, Korea
* Correspondence: noshin@hanyang.ac.kr (D.W.J.); eug203@korea.ac.kr (S.Y.Y.)
† These authors contributed equally to this work.

Abstract: DAA therapy is known to clear hepatitis C virus infection in patients with decompensated cirrhosis (DC). However, the safety and benefits of DAA in DC remain unclear, especially with the use of protease inhibitors (PI). Therefore, we evaluated the efficacy and clinical safety of DAA in DC patients and observed whether there was a discrepancy between PI-based and non-PI-based treatment. We searched Ovid-Medline, Ovid-EMBASE, Cochrane Library, and three local medical databases through October 2021 to identify relevant studies on the clinical safety and effectiveness of DAA in DC patients. The outcomes were sustained virologic response (SVR), overall mortality, the incidence rate of hepatocellular carcinoma (HCC), adverse events, improvement or deterioration of liver function, and delisting from liver transplantation (LT). Two independent reviewers extracted the data from each study using a standardized form. The pooled event rate in DC patients and relative effect (odds ratio (OR)) of PI-treated versus non-PI-based DAA in DC patients were calculated using a random-effects model. In patients with DC, the SVR rate was 86% (95% CI 83–88%), the development of HCC 7% (95% CI 5–9%), and mortality 6% (95% CI 4–8%). Improvement in liver function was observed in 51% (95% CI 44–58%) of patients, and 16% (95% CI 5–40%) were delisted from LT. PI-based treatment showed a similar rate of serious adverse events (23% vs. 18%), HCC occurrence (5% vs. 7%), and mortality (5% vs. 6%) to that of non-PI-based DAA treatment in DC patients. HCC occurrence and mortality rates were low in patients with DC following DAA treatment. PI-based treatment in DC patients was relatively safe when compared to non-PI-based treatment. Overall, DAA improved liver function, which may have allowed for delisting from LT.

Keywords: chronic hepatitis C; decompensated liver cirrhosis; direct-acting antiviral; protease inhibitor

1. Introduction

It is estimated that 71 million people worldwide live with hepatitis C virus (HCV) [1], and 0.6% of the Korean population is chronically infected with HCV [2]. HCV infection is an important issue since 70% of untreated patients develop chronic HCV infection, and the risk of cirrhosis ranges from 15 to 30% within 20 years [1]. However, the progression to cirrhosis is often clinically silent, and some patients are unaware of the HCV infection. Asymptomatic liver cirrhosis may ultimately lead to decompensated cirrhosis (DC) with an annual risk of 3–5% and hepatocellular carcinoma (HCC). DC is a life-threatening condition.
with a mortality rate of 70% within 5 years, and liver transplantation is the only treatment available to avoid death [3].

In the interferon (IFN) era, treatment was limited to patients with either chronic hepatitis C (CHC) or compensated cirrhosis owing to safety concerns. IFN-based treatment in DC is associated with lower sustained virologic response (SVR) and increased risk of sepsis and hepatic encephalopathy, leaving patients with DC without tolerable treatment options [4,5]. The introduction of direct-acting antivirals (DAAs) has revolutionized the treatment of chronic HCV infection, and the efficacy and safety of DAA have been proven even in patients with compensated cirrhosis [6–10].

However, according to the U.S. Food and Drug Administration (FDA) report, some patients with compensated cirrhosis treated with protease inhibitors (PI) based DAA, such as paritaprevir/ritonavir/ombitasvir, developed jaundice and rapidly progressed to liver failure within 1–4 weeks of initiation of treatment [11]. A multicenter cohort study in Israel found that seven patients treated with paritaprevir/ritonavir/ombitasvir developed decompensation within 1–8 weeks of initiation of treatment, and one of these patients died [12]. Therefore, paritaprevir/ritonavir/ombitasvir ± dasabuvir is contraindicated in all patients with compensated cirrhosis because of concerns about hepatotoxicity. Additionally, data on the use of simeprevir in patients with Child–Turcotte–Pugh (CTP) class B cirrhosis are limited. In a phase 2 study comprising 40 patients (19 CTP class A and 21 CTP class B patients) treated with simeprevir, sofosbuvir, and daclatasvir for 12 weeks, the mean pharmacokinetic exposure to simeprevir was 2.2-fold greater after 8 weeks of treatment in CTP B than A [13,14]. It was higher in CTP class B than in CTP class A cirrhosis patients. Although all patients achieved SVR12, grade 3 or 4 bilirubin elevations were observed in 18% and 5% of the patients, respectively, although they were not associated with an increase in alanine transaminase (ALT) or the need for drug discontinuation.

Very recently, Torgerson et al. reported that PI-based DAAs are safe and do not increase the risk of hepatic decompensation compared to non-PI DAAs [15]. However, the number of decompensated patients included in that study was unclear. Patients with mild or well-compensated cirrhosis were included. Further studies are needed to confirm the safety and efficacy of PI-based DAAs.

Studies evaluating the efficacy of DAA in DC have been conducted. However, controversy exists regarding the treatment of patients with DC. In this study, we aimed to evaluate the efficacy and clinical safety of DAA in DC patients and to analyze whether PI-based DAA in DC patients resulted in a worse prognosis than non-PI-based treatment based on the results that have been published.

2. Materials and Methods

The review followed the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) guidelines [16].

2.1. Data Sources and Searches

We conducted literature searches of CHC treated with DAA in Ovid-MEDLINE, Ovid-Embase, Cochrane Register of Controlled Trials (CENTRAL), and three local Korean databases for articles published until 31 October 2021. As the first DAAs were approved by the FDA in 2011 [17], studies published before 2010 were excluded. The included DAAs were sofosbuvir, sofosbuvir and ribavirin, simeprevir, daclatasvir; ledipasvir, glecaprevir, pibrentasvir, elbasvir, grazoprevir, dasabuvir, velpatasvir, and ombitasvir/paritaprevir/ritonavir. The search terms were index terms and text words related to CHC or DAA. A search filter was applied and recommended by the Scottish Intercollegiate Guidelines Network to efficiently identify randomized controlled trials and observational studies. We applied no language limitations in the electronic database search, which was restricted to studies involving humans. Detailed search strategies for each database are provided in the Supplementary Material. The bibliographies of relevant articles were searched to identify additional publications. The protocol for this review
was registered in advance in the International Prospective Register of Systematic Reviews (CRD42021241245). The review followed the PRISMA guidelines and the Meta-Analysis of Observational Studies in Epidemiology (MOOSE) checklist.

2.2. Definition

DC was defined by the presence of Child–Pugh B or C cirrhosis, ascites, hepatic encephalopathy, hepatic hydrothorax, and variceal hemorrhage, while those without complications as mentioned above and with Child–Pugh A cirrhosis were grouped as compensated cirrhosis (CC) patients.

SVR was defined as undetectable HCV RNA in the blood 12 weeks after antiviral therapy completion. Adverse events (AEs) were defined as any new symptoms during the treatment period independent of the requirement for dose reduction or treatment discontinuation. Serious AEs were adopted for analysis when they were mentioned in the study. Re-compensation of decompensated liver cirrhosis was defined as the restoration of cirrhosis status to Child–Pugh A, decrease in Model for End-Stage Liver Disease (MELD) score, or portal hypertension.

The use of PI in more than 20% of DC patients was classified as the PI-based treatment group, while those treated with less than 20% were categorized as the non-PI-based treatment group.

2.3. Study Selection

Studies reporting DAA patients with chronic HCV cirrhosis were considered eligible for inclusion. No restrictions on the subjects’ age, biological sex, or viral genotype were included in the study. All DAA regimens used worldwide were considered in the meta-analysis and were not limited to those approved by specific governments or institutions. Various prospective and retrospective studies, including randomized controlled trials, nonrandomized clinical trials, case-control studies, case-series studies, and cohort studies, have been included. Two reviewers (SYY and JHA) independently reviewed titles and abstracts. Full-text documents were independently examined after screening the titles and abstracts.

2.4. Data Extraction

The two reviewers who conducted the study selection independently extracted data from the selected studies into a standardized form, including (1) study characteristics: authors, year of publication, study location, design, and setting; (2) study population: number of compensated and decompensated liver cirrhosis patients, age, HCV genotype, and prior IFN treatment; (3) intervention: DAAs; and (4) outcome: SVR, improvement in liver function, AEs, discontinuation of DAA, development of HCC, death, and delisting from liver transplantation. Any disagreement between the two reviewers was resolved through discussion with a third reviewer (DAP or DWJ).

2.5. Risk of Bias Assessment

The risk of bias was assessed in selected studies using the Risk of Bias for Nonrandomized Studies (RoBANS) ver 2.0. Further information on the process and results of the risk of bias assessment are provided in the Supplementary Material. Two or three demonstrations of risk assessment were conducted. The risk of bias assessment was independently performed by two reviewers (SSY, JHA), and any discrepancy was resolved through a discussion with a third reviewer (JJY or SBA).

2.6. Statistical Analysis

The primary outcomes of this study were pooled event rate of (1) SVR; (2) serious adverse events (SAEs); (3) discontinuation of DAA; (4) HCC occurrence; (5) improvement in liver function; (6) delisting from liver transplantation; and (7) death in patients with DC. For dichotomous outcomes, the odds ratios (ORs) were calculated and reported with
95% confidence intervals (CIs) between PI-based DAA and non-PI-based DAA in DC patients. The pooled event rate was calculated in studies with only patients with DC. Heterogeneity among studies was initially determined by individual forest plots and later confirmed by Cochran’s Q statistic ($p < 0.10$, $I^2 \geq 50\%$). Given the variability of the patients’ characteristics within the studies, the random-effects model was always applied as a conservative approach to all variables, regardless of $I^2$ statistical data. Sensitivity and subgroup analyses were used to investigate the sources of heterogeneity and the factors that affected the magnitude of the effect. We prespecified and conducted subgroup analyses according to the specific characteristics of the study methods, study populations, and interventions. Egger’s test and funnel plot were used to detect publication biases associated with the variables used in $\geq 10$ studies. Statistical analyses were performed with Review Manager, version 5.3 (RevMan, Copenhagen: The Nordic Cochrane Center) and the “meta” and “metafor” packages on the R version 3.6.3 (R Foundation for statistical software, version 3.6.3).

3. Results

3.1. Study Characteristics

Based on the database searches, 13,185 records were identified using a systematic review (Figure 1). After removing duplicates, 2803 records were checked for titles or abstracts, and 1690 studies were excluded after a thorough examination, of which 60 studies met the inclusion criteria after full-text review (Figure 1). No relevant articles were identified from the reference lists of review articles or meta-analyses.

![Figure 1. Flowchart of study selection for the systematic review and meta-analysis.](image-url)
| Author, Year | Study Location | Publication Type | Study Design | Total Patients | Age (Years) | Gender (Male) | Prior Treatment (%) | CC | DC | GT | DAA | PI-Based (≥20%) | FU Period | References |
|--------------|----------------|------------------|-------------|---------------|------------|---------------|------------------|----|----|----|-----|----------------|------------|------------|
| Afdhal, 2017 | Worldwide      | Original         | Prospective | 50            | 55 (43–69) | 76%           | 68%             | 18 | 32 | 1-4 | SOF/RBV | No             | NA         | [18]       |
| Alonso, 2017 | Spain          | Original         | Retrospective | 208           | 55 ± 8     | 82%           | 47%             | 166| 42 | 3   | SOF/LDV ± RBV, SOF/DCV ± RBV | No | 12 wks | [19]       |
| Backus, 2016 | China          | Original         | Retrospective | 6542          | 61.4 ± 6.2 (24.5–90.8) | 96% | 24% | 6333 | 209 | 1 | LDV/SOF ± RBV, PTV/r/DSV/RBV | No | NA | [20]       |
| Berkan-Kawinska, 2021 | Europe | Original | Prospective | 2713 | 59 (50–65) | 54% | 41% | 2397 | 316 | 1-6 | LDV/SOF ± RBV, OBV/PTV/r ± DSV ± RBV, GLE/PIB, SOF/VEL ± RBV, SOF/IFN/RBV, SOF/RBV, ASV/DCV | Yes | At least 12 wks | [21] |
| Calleja, 2017 | Spain          | Original         | Retrospective | 3325          | 59.5 (21–87) | 55% | 45% | 2362 | 136 | 1 | OMV/PTV/r ± DSV ± RBV, SOF/LDV ± RBV | No | 24 or 36 wks | [22] |
| Calvaruso, 2018 | Italy | Original | Prospective | 2249 | 6.4 ± 10.7 | 57% | 56% | 2035 | 214 | 1-4 | SOF/SIM, SOF/DCV, SOF/LDV, SOF/VEL ± RBV | No | 14 (6–24) mo | [23] |
| Carrillo, 2017 | Spain          | Original         | Retrospective | 739           | 55 (36–80) | 67% | 60% | 564 | 175 | 1/3 | SOF/SIM, SOF/DCV, SOF/LDV, OBV/PTV/r/DSV, SIM/DCV | Yes | 12 wks | [24] |
| Chatterjee, 2019 | India | Abstract | Prospective | 50            | 55         | 62% | 28% | 21  | 29  | 1/3 | SOF/LDV/DCV, SOF/VEL ± RBV | No | 2 yrs | [25] |
| Cheung, 2016 | UK             | Original         | Prospective | 406           | 54 (28–79) | NA   | NA  | 70  | 406 | 1/3 | SOF/LDV ± RBV, SOF/VEL ± RBV | No | 15 mo | [26] |
| Deterding, 2015 | Germany | Original | Prospective | 80            | 57 ± 9 (range 38–79) | 59% | 68% | 45  | 34  | 1-4 | SOF/RBV, SOF/SIM ± RBV, SOF/DCV ± RBV | NA | 12 wks | [27] |
| Garg, 2018 | India           | Original         | Prospective | 63            | 47.2 ± 11.5 (32–75) | 56% | 0   | 33  | 30  | 3 | SOF/LDV ± RBV | No | 15 mo | [28] |
| Goel, 2017 | India           | Original         | Prospective | 160           | 45 (18–75) | 39% | 10% | 31 (CHC79) | 51 | 3 | SOF/RBV, SOF/DCV, SOF/DCV/RBV | No | 12/24 wks | [29] |
| Gupta, 2018 | India           | Original         | Prospective | 490           | 38.9 ± 12.7 | 57% | 12% | 120 (CHC339) | 31 | 1-4 | SOF/RBV, SOF/SIM ± RBV, SOF/DCV, SOF/DCV/RBV | No | 12 wks | [30] |
| Ibrahim, 2021 | Egypt          | Original         | Retrospective | 601           | 50.54 ± 12.82 | 37% | 18% | 275 | 326 | 4 | DAA | NA | 12 wks | [31] |
| Jacobson, 2019 | USA            | Original         | Prospective | 40            | 58.3 ± 7 | 57% | 37% | 10  | 30  | 1 | EBR/GZR | Yes | 12 wks | [32] |
| Kraassenburg, 2020 | Worldwide | Original | Retrospective | 868           | 59 (54–65) | 64% | 12% | 719 | 149 | 1-6 | NS3/4 NS5A, NS3/4 NS5B, NS3/4 NS5A/B NS5B NS5A/B | No | 28 (IQR 20–36) | [33] |
Table 1. Cont.

| Author, Year | Study Location | Publication Type | Study Design | Total Patients | Age (Years) | Gender (Male) | Prior Treatment (%) | CC | DC | GT | DAA | PI-Based (≥20%) | FU Period | References * |
|--------------|----------------|------------------|--------------|----------------|-------------|---------------|---------------------|----|----|----|-----|---------------|-----------|--------------|
| Kumada, 2021 | UK and Japan   | Original         | Prospective  | 364            | 54 (48–59)  | 72%           | 0                   | 50 | 50 | 314 | 1-4 | LDV/SOF ± RBV, SOF/DCV ± RBV | No        | 1.75 (0.71–3.05) yrs | [33] |
| Kwo, 2018    | USA            | Original         | Retrospective| 77             | 63 (34–79)  | 78%           | 56%                  | 63 | 14 | 1-3 | DCC/BOF ± RBV | No            | 24 wks    | [34] |
| Lens, 2017   | Spain          | Original         | Retrospective| 922            | 72 (65–90)  | 58%           | 48%                  | 746 | 176 | 1-4 | SOF/RBV, LDV/SOF ± RBV, SOF/SIM ± RBV, DCV ± RBV, PTV/ORBV/RBV, OBV/PTV/DSV ± RBV | NA        | 12 wks       | [35] |
| Lens, 2020   | Spain          | Original         | Prospective  | 226            | 60 (53–69)  | 53%           | NA                   | 179 | 47 | 1-5 | LDV/SOF ± RBV, SOF/SIM ± RBV, SOF/DCV ± RBV | NA        | 24, 96 wks   | [36] |
| Lim, 2018    | USA            | Original         | Prospective  | 634            | >65 (153 (24%) | 66%           | 100%                 | 383 | 251 | 1   | LDV/SOF ± RBV | No            | 12 wks    | [37] |
| Lobato, 2019 | Brazil         | Original         | Prospective  | 3939           | 58 ± 10      | 60%           | NA                   | 3703 | 236 | 1-6 | SOF/DCV, SOF/SIM, SOF/LDV, OBV/PTV/r/DSV ± RBV, SOF/RBV/Peg-INF | NA        | 12, 24 mo    | [38] |
| Maan, 2016   | Worldwide      | Original         | Retrospective| 433            | 57.8 ± 8.7   | 64%           | 65%                  | 319 | 114 | 1-5 | PL, DAA/RBV | Yes           | 12 wks    | [39] |
| Macken, 2019 | UK             | Original         | Prospective  | 1448           | 54 (47–60)  | 73%           | 41%                  | 1344 | 104 | 1/3 | O/BV/PTV/r/DSV ± RBV, SOF/LDV ± RBV, SOF/DCV ± RBV, SOF/Peg-INF | NA        | 12 wks       | [40] |
| Mandorfer, 2016 | Austria       | Original         | Retrospective| 120            | 52.6 ± 1.2   | 73%           | NA                   | 60  | 60 | 1-4 | SOF/RBV, SOF/SIM, SOF/DCV, SOF/LDV, SIM/DCV | NA        | 12 wks       | [41] |
| Mangia, 2018 | Worldwide      | Abstract         | Prospective  | 1545           | 59 (26–86)  | 68%           | NA                   | 1318 | 227 | NA  | DAA | NA            | 23 (c.1–144) wks | [42] |
| Mazzarelli, 2018 | UK           | Original         | Retrospective| 113            | >65 (153 (24%) | 53%           | 61%                  | 101 | 12 | 1-4 | SOF/LDV ± RBV, SOF/DCV ± RBV, SOF/RBV, OBV/PTV/r/DSV ± RBV | NA        | 38 wks (12–132) | [43] |
| Papaioanou, 2017 | Greece        | Abstract         | Retrospective| 604            | 57 ± 11      | 58%           | 67%                  | 386 (1CHC158) | 60 | 1-5 | SOF/SIM ± RBV, SOF/DCV ± RBV, SOF/SIM ± RBV, SOF/DCV ± RBV, 2D/3D ± RBV | Unknown  | NA          | [44] |
| Pascasio, 2017 | Spain         | Original         | Retrospective| 171            | 54 (51–61)  | 81%           | 49%                  | 17  | 154 | 1,3,4 | SOF/RBV, SOF/DCV ± RBV, SOF/SIM ± RBV, SOF/LDV ± RBV, 2D/3D ± RBV | No        | NA          | [45] |
| Poordad, 2016 | USA            | Original         | Prospective  | 60             | 58 (19–75)  | 63%           | 60%                  | 12  | 48 | 1-6 | DCV/SOF/RBV | No            | 24 wks    | [46] |
| Ridrueco, 2019 | Argentina     | Original         | Prospective  | 906            | 60 ± 12      | 52%           | 55%                  | 486 | 91  | 1-4 | SOF/DCV ± RBV | No            | 22.3 mo   | [47] |
Table 1. Cont.

| Author, Year | Study Location | Study Type | Study Design | Total Patients | Age (Years) | Gender (Male) | Prior Treatment (%) | CC | DC | GT | DAA | PI-Based (≥20%) | FU Period | References |
|--------------|----------------|------------|--------------|----------------|-------------|---------------|---------------------|----|----|----|-----|-----------------|-----------|------------|
| Sanai, 2018  | Arab           | Original   | Prospective  | 213            | 59.6 ± 12.1 | 41%           | 40%                 | 165| 48| 4  | SOF/LDV ± RBV   | No               | 12 wks     | [48]       |
| Saxena, 2015 | USA            | Original   | Retrospective| 156            | 61 (58–64)  | 61%           | 55%                 | 101| 55| 1  | SOF/SIM ± RBV   | Yes              | 12 wks     | [49]       |
| Shiffman, 2015| USA            | Original   | Retrospective| 120            | 60 (29–79)  | 63%           | 51%                 | 81 | 39| 1  | SIM/SOF          | NA               | 24 mo      | [50]       |
| Steinebrunner, 2018 | Germany | Original | Retrospective | 199            | 59 ± 10, (27–85) | 67% | 56% | 152 | 47 | 1–4 | SOF/LDV ± RBV, PTV/r/OMV/DSV ± RBV | NA | 12 wks | [51] |
| Tahata, 2021  | Japan          | Original   | Prospective  | 190            | 68 (40–87)  | 52%           | 57%                 | 108| 82| 1–4 | LDV/SOF, EBR/GZR, GLE/PIB, SOF/VEL, SOF/VEL ± RBV | No | 12 wks | [52] |
| Terrault, 2016 | USA            | Original   | Prospective  | 2255           | 60 (18–87)  | 60%           | 50%                 | 917 (CHC924) | 414| 1  | SOF/LDV/BBV     | No               | 12         | [53]       |
| Tmu, 2019     | India          | Original   | Retrospective| 103            | 50 (29–82)  | 64%           | 18%                 | 26 (CHC28) | 47 | 1,2 | SOF/VEL         | No               | 12 wks     | [54]       |
| Verna, 2020   | Worldwide      | Original   | Prospective  | 642            | 60 (25–89)  | 68%           | 65%                 | 178| 393| 4  | SOF/LDV, SOF/DCV, SOF/VEL, EBR/GZR | No | 12 wks | [55] |
| Wei, 2020     | China          | Original   | Prospective  | 222            | 58.9 ± 10.7 | 50%           | 9%                  | 31 (CHC165) | 26 | 1–6 | OBV/PTV/r/DSV, SOF/VEL ± RBV, SOF/VEL ± RBV, SOF/VEL, EBR/GZR, DCC/ASV, GLE/PIB ± RBV | No | Median, 36 wks | [56] |
| Welzel, 2016  | Germany        | Original   | Retrospective| 485            | 57 (27–87)  | 66%           | 70%                 | 223 (CHC97) | 165| 1–5 | DCV/SOF ± RBV   | No               | 12 wks     | [57]       |
| Belli, 2016   | Europe         | Original   | Retrospective| 103            | 54 (34–71)  | 68%           | NA                  | 0  | 103| 1–3 | SOF/VEL ± RBV, SOF/LDV ± RBV, SOF/SIM ± RBV | No | 51.9 (22.9–47.4) wks | [58] |
| Belli, 2018   | Europe         | Original   | Retrospective| 36,382         | 54 (34–71)  | 69%           | NA                  | 0  | 36,382| NA | Protease inhibitor | NA | NA | [59] |
| Bittermann, 2021 | USA         | Original   | Retrospective| 8394           | 57 (53–61)  | 70%           | NA                  | 0  | 8394| NA | DAA            | NA               | NA          | [60]       |
| Charlton, 2015 | USA            | Original   | Prospective  | 108            | 59 (55–62)  | 67%           | 65%                 | 0  | 108| 1  | SOF/LDV/VEL     | No               | NA         | [9]        |
| Curry, 2015   | USA            | Original   | Prospective  | 267            | 58 (40–73)  | 70%           | 55%                 | 0  | 267| 1–6 | SOF/VEL ± RBV   | No               | 12 wks     | [5]        |
| Curry, 2016   | Worldwide      | Abstract   | Prospective  | 667            | NA           | NA            | NA                  | 0  | 667| 1/4 | SOF/LDV         | No               | 12 wks     | [61]       |
| Debnath, 2019 | India          | Abstract   | Retrospective| 62             | Median 48    | 54%           | NA                  | 0  | 62 | NA | SOF/VEL, LDV VEL ± RBV | No | 24 wks | [62] |
| El-Sherif, 2018 | Worldwide | Original | Prospective  | 622            | 59 (54–62)  | 72%           | NA                  | 0  | 622| 1–4 | SOF/LDV/VEL/SOF ± RBV, SOF + RBV | No | 255 (251–236) days | [63] |
| Author, Year | Study Location | Publication Type | Study Design | Total Patients | Age (Years) | Gender (Male) | Prior Treatment (%) | CC | DC | GT | DAA | PI-Based (≥20%) | FU Period | References * |
|--------------|----------------|-----------------|-------------|----------------|-------------|---------------|---------------------|----|----|----|-----|-----------------|------------|--------------|
| Flemming, 2017 | USA | Original | Retrospective | 47,591 | 56 (IQR, 51–61) | 71% | NA | 0 | 33,947 | NA | DAA, PI | NA | NA | [64] |
| Foster, 2016 | UK | Original | Prospective | 409 | 54 (28–80) | 73% | 61% | 0 | 409 | 1/3 | SOF/LDV ± RBV, SOF/DCV ± RBV | No | 12 wks | [26] |
| Gentile, 2019 | Italy | Original | Prospective | 89 | 72 (67–76) | 46% | 42% | 0 | 89 | 1-4 | SOF/LDV SOF/RBV SOF/DCV | No | 11 months | [65] |
| Hanafy, 2019 | Egypt | Original | Retrospective | 160 | 51.4 ± 6.3 | 78% | 0 | 0 | 160 | 4 | SOF/DCV/RBV | No | 29.3 ± 1.9 mo | [66] |
| Lin, 2018 | China | Abstract | Retrospective | 56 | 63.6 ± 8.1 | 39% | 24% | 0 | 56 | 1-3 | SOF/LDV SOF/RBV | No | 12.5 ± 7.3 months | [63] |
| Lourenco, 2021 | Brazil | Original | Retrospective | 85 | 56.13 ± 11.14 | 51% | 54% | 0 | 85 | 1-3 | SOF/DCV ± RBV, SOF/SIM ± RBV | No | 12-24 wks | [67] |
| Manolakopoulos, 2017 | Greece | Abstract | Retrospective | 126 | 59 ± 12.82 | 62% | 56% | 0 | 126 | 1-3 | SOF/SIM, SOF/DSV, SOF/LDV, 3D/2D, SOF/VEL, EBR/GZP | No | 12 wks | [68] |
| McCaughan, 2017 | Australia | Original | Prospective | 108 | 56 (51–61) | 73% | 40% | 0 | 108 | 1-4 | SOF/DCV ± RBV | No | 12 wks | [69] |
| Modi, 2016 | USA | Original | Prospective | 42 | 58 (32–69) | 74% | 52% | 0 | 42 | 1 | SOF/SIM ± RBV | Yes | 12 wks | [70] |
| Mohamed Essa, 2019 | Egypt | Original | Retrospective | 75 | >60.20 (26.7) | 69% | NA | 0 | 75 | NA | SOF/DCV, SOF/LDV ± RBV | No | 6 mo | [71] |
| Sandmann, 2018 | Worldwide | Original | Retrospective | 35 | 55.5 ± 8.97 | 80% | 54% | 0 | 35 | 1-4 | SOF/DCV ± RBV, SOF/SIM, SOF/LDV ± RBV, PTV/r/OBV/DSV | No | 18 (IQR 8–29) mo | [72] |

Abbreviations: CC, compensated cirrhosis; DC, decompensated cirrhosis; GT, genotype; DAA, direct antiviral agent; FU, follow-up; NA, not applicable; PI, protease inhibitor; SVR, sustained virologic response; EOT, end of treatment; IQR, interquartile range; Wks, weeks; mo, months; NA, not available; SOF, sofosbuvir; RBV, ribavirin; r, ritonavir; SIM, simeprevir; DCV, daclatasvir; LDV, ledipasvir; GLE, glecaprevir; PIB, pibrentasvir; EBR, elbasvir; GZR, grazoprevir; 2D, OBV/PTV/r; 3D, OBV/PTV/r + DSV; OBV, ombitasvir; PTV, paritaprevir; DSV, Dasabuvir; VEL, Velpatasvir. * References are found in the Supplementary Data.
Sixty studies including patients with HCV cirrhosis were conducted in 14 different countries, and nine (22%) studies were based on Asian data. Thirty studies were prospective cohort studies, and thirty were retrospective cohort studies. Forty studies included a history of prior treatment with IFN, and fifteen studies included PI-based treatment. Of the 60 studies, 41 included both DC and CC patients, while nine included DC patients only. Details of the study, including patient characteristics, types of DAA, and observed outcomes, are described in Table 1.

3.2. Risk of Bias Graph

The risk of bias is shown in Supplementary Figure S1. Except for the selection of participants, most categories showed a low risk of bias, whereas comparability of patients and selective outcome reporting showed some proportion of unclear risk of bias.

3.3. Efficacy and Safety of DAA in DC Patients

Forty-nine studies, including 7886 patients with DC, included data on SVR following DAA treatment. Pooled analysis showed that the SVR rate was 86% (95% CI: 0.83–0.88) (Figure 2A). Patients were divided according to age, previous history of IFN treatment, use of PI-based DAs, HCV genotypes, study design, industrial sponsorship, and study region, and for all of them, the SVR did not differ (Table 2).

Table 2. Summary of the estimated effect of the sustained virologic response of direct-acting antiviral (DAs) in decompensated cirrhosis patients with chronic hepatitis C virus (HCV) infection.

| Outcomes                        | No. of Studies | Pooled Event Rate | 95% CI     | I² (%) |
|---------------------------------|----------------|-------------------|------------|--------|
| SVR, overall                    | 49             | 0.86              | 0.83–0.88  | 68     |
| Age (years)                     |                |                   |            |        |
| ≥60                             | 14             | 0.87              | 0.81–0.92  | 78.3   |
| <60                             | 35             | 0.84              | 0.82–0.87  | 66.1   |
| Previous interferon treatment   |                |                   |            |        |
| Yes                             | 3              | 0.85              | 0.83–0.88  | 71.9   |
| No                              | 11             | 0.88              | 0.79–0.93  | 82.6   |
| Protease inhibitor based        |                |                   |            |        |
| Yes                             | 6              | 0.85              | 0.75–0.91  | 78.7   |
| No                              | 37             | 0.86              | 0.84–0.89  | 74.4   |
| Genotype                        |                |                   |            |        |
| GT 1                             | 7              | 0.86              | 0.77–0.92  | 75.7   |
| GT 3                             | 3              | 0.8               | 0.45–0.95  | 50.5   |
| GT 4                             | 3              | 0.88              | 0.82–0.92  | 0      |
| GT Mixed                        | 35             | 0.85              | 0.82–0.88  | 77.1   |
| Study design                     |                |                   |            |        |
| Prospective                     | 25             | 0.86              | 0.83–0.89  | 70.9   |
| Retrospective                   | 23             | 0.84              | 0.80–0.88  | 73.1   |
| Industrial sponsorship          |                |                   |            |        |
| Yes                             | 27             | 0.86              | 0.83–0.89  | 77.7   |
| No                              | 22             | 0.85              | 0.8–0.88   | 71     |
| Study region                     |                |                   |            |        |
| Asia                            | 9              | 0.87              | 0.77–0.93  | 57.6   |
| USA                             | 11             | 0.85              | 0.79–0.89  | 67.4   |
| Europe                          | 14             | 0.86              | 0.81–0.9   | 79.1   |
| Others                          | 15             | 0.86              | 0.8–0.88   | 71     |

We also analyzed the safety of DAs in patients with DCs. The pooled rate for AEs and SAEs were 55% and 22%, respectively (n = 13 studies, 95% CI: 0.31–0.77 and n = 12 studies, 95% CI: 0.13–0.36, respectively) (Table 3, Figure 2B,C). AEs that resulted in drug discontinuation
were further analyzed, and the pooled rate reached 6% (n = 11 studies, 95% CI: 0.04–0.08). The pooled rate for the development of HCC was 7% (n = 14, 95% CI: 0.05–0.09), and the overall mortality was 6% (n = 28, 95% CI: 0.04–0.08) in DC patients (Figure 2D,E).

(A)

| Study | Events | Total | Proportion | 95% CI | Weight |
|-------|--------|-------|------------|--------|--------|
| Bergen-Klasta et al., 2021 | 261 | 281 | 0.93 | [0.88–0.98] | 2.5% |
| Ekelith, 2021 | 283 | 326 | 0.87 | [0.83–0.90] | 2.6% |
| Kozak, 2021 | 583 | 653 | 0.88 | [0.83–0.93] | 5.0% |
| Larcomo, 2021 | 74 | 77 | 0.96 | [0.90–0.99] | 1.1% |
| Tahaka, 2021 | 54 | 82 | 0.93 | [0.82–0.99] | 1.0% |
| Kieback, 2020 | 120 | 119 | 0.51 | [0.47–0.57] | 2.5% |
| Versa, 2020 | 122 | 127 | 0.90 | [0.86–0.93] | 2.5% |
| Wu, 2030 | 35 | 28 | 0.98 | [0.90–1.00] | 0.5% |
| Ch interle, 2016 | 24 | 29 | 0.83 | [0.75–0.90] | 1.5% |
| Gendal, 2019 | 89 | 89 | 0.90 | [0.86–0.94] | 1.4% |
| Hardy, 2016 | 144 | 160 | 0.91 | [0.84–0.98] | 2.4% |
| Jakobsson, 2019 | 27 | 50 | 0.91 | [0.79–0.98] | 1.2% |
| Leiner, 2019 | 50 | 66 | 0.76 | [0.64–0.86] | 2.3% |
| Mohammadi Esho, 2019 | 75 | 75 | 1.00 | [0.95–1.00] | 0.3% |
| Much, 2019 | 62 | 91 | 0.92 | [0.80–0.97] | 2.0% |
| Tsch, 2018 | 27 | 34 | 0.79 | [0.60–0.91] | 1.7% |
| Callebaut, 2018 | 188 | 214 | 0.85 | [0.75–0.94] | 2.6% |
| El-Din, 2016 | 528 | 622 | 0.85 | [0.75–0.94] | 3.0% |
| Gler, 2018 | 30 | 41 | 0.73 | [0.57–0.87] | 2.0% |
| Gup, 2019 | 30 | 39 | 0.87 | [0.73–0.99] | 0.9% |
| Kive, 2016 | 8 | 13 | 0.62 | [0.32–0.99] | 1.2% |
| Lee, 2018 | 213 | 231 | 0.92 | [0.85–0.97] | 2.5% |
| Lee, 2019 | 51 | 52 | 0.98 | [0.94–1.00] | 0.5% |
| Sear, 2018 | 43 | 48 | 0.90 | [0.77–0.97] | 1.5% |
| Sennema, 2018 | 22 | 30 | 0.73 | [0.54–0.90] | 1.9% |
| Almand, 1997 | 18 | 16 | 0.96 | [0.86–1.00] | 1.6% |
| Alnes, 2017 | 38 | 42 | 0.92 | [0.77–0.99] | 1.4% |
| Carrillo, 2017 | 112 | 114 | 0.98 | [0.90–1.00] | 2.7% |
| Cleal, 2017 | 23 | 30 | 0.77 | [0.59–0.94] | 1.7% |
| Lera, 2017 | 140 | 178 | 0.83 | [0.72–0.90] | 2.7% |
| Metcalfe, 2017 | 97 | 138 | 0.71 | [0.56–0.88] | 2.7% |
| Mccaughan, 2017 | 80 | 75 | 0.70 | [0.56–0.86] | 2.4% |
| Pepelko, 2017 | 175 | 205 | 0.70 | [0.59–0.82] | 2.7% |
| Pasque, 2017 | 192 | 225 | 0.83 | [0.77–0.92] | 2.9% |
| Birk, 2016 | 173 | 258 | 0.83 | [0.77–0.92] | 2.9% |
| Bolk, 2016 | 98 | 100 | 0.98 | [0.93–1.00] | 0.9% |
| Oem 2016 | 328 | 408 | 0.81 | [0.71–0.90] | 2.0% |
| Currey, 2016 | 47 | 50 | 0.90 | [0.80–0.98] | 1.4% |
| Ponsai, 2016 | 361 | 467 | 0.75 | [0.65–0.85] | 3.0% |
| Mark, 2016 | 83 | 101 | 0.82 | [0.72–0.90] | 2.4% |
| Mcc, 2016 | 37 | 42 | 0.89 | [0.74–0.99] | 1.5% |
| Pontes, 2016 | 30 | 48 | 0.61 | [0.47–0.76] | 0.9% |
| Tettard, 2017 | 283 | 296 | 0.91 | [0.80–1.00] | 2.7% |
| Wood, 2018 | 131 | 119 | 0.85 | [0.71–0.99] | 2.6% |
| Clarke, 2015 | 45 | 52 | 0.87 | [0.75–0.99] | 1.6% |
| Curry, 2015 | 339 | 287 | 0.85 | [0.76–0.93] | 2.7% |
| Saver, 2015 | 37 | 49 | 0.79 | [0.62–0.97] | 2.1% |
| Griffin, 2015 | 29 | 38 | 0.72 | [0.52–0.92] | 2.0% |
| Caliys, 2016 | 176 | 206 | 0.93 | [0.87–0.99] | 2.1% |

Any AE

(B)

| Study | Events | Total | Proportion | 95% CI | Weight |
|-------|--------|-------|------------|--------|--------|
| Bergen-Klasta et al., 2021 | 144 | 316 | 0.46 | [0.40–0.51] | 3.3% |
| Larcomo, 2021 | 44 | 160 | 0.58 | [0.50–0.65] | 9.2% |
| Verly, 2020 | 498 | 642 | 0.75 | [0.69–0.82] | 7.0% |
| Wri, 2020 | 8 | 22 | 0.36 | [0.22–0.50] | 7.5% |
| Cereiba, 2019 | 26 | 80 | 0.32 | [0.25–0.39] | 8.2% |
| JACC, 2019 | 26 | 33 | 0.78 | [0.60–0.95] | 7.4% |
| Greg, 2010 | 12 | 30 | 0.43 | [0.23–0.59] | 7.5% |
| Hoo, 2018 | 14 | 14 | 1.00 | [0.71–1.00] | 4.4% |
| Dottor, 2016 | 216 | 408 | 0.52 | [0.47–0.57] | 8.3% |
| Mod, 2016 | 48 | 42 | 0.43 | [0.29–0.57] | 6.9% |
| Charro, 2015 | 139 | 139 | 1.00 | [0.81–1.00] | 6.9% |
| Curry, 2015 | 25 | 267 | 0.09 | [0.06–0.13] | 8.2% |
| Cerrine, 2015 | 12 | 50 | 0.22 | [0.12–0.33] | 6.0% |

Random effects model: 0.01

Figure 2. Cont.
Figure 2. Estimated event rate of (A) the sustained virologic response, (B) any adverse events, (C) serious adverse events, (D) development of hepatocellular carcinoma, and (E) mortality in decompensated liver cirrhosis patients treated with direct-acting antiviral (DAA).
When the efficacy of DAA in DC was compared to that of CC patients based on 30 studies, patients with decompensated cirrhosis showed a lower SVR rate (OR 0.43, 95% CI: 0.34–0.54) than CC patients. Furthermore, the protective effect of DAA on HCC development and mortality was also less significant in DC patients than in CC patients (n = 6, OR 2.67, 95% CI: 1.88–3.79 and n = 11, OR 6.14, 95% CI: 4.24–8.89, respectively) (Supplementary Figure S2A–C).

Table 3. Summary of outcomes for patients with decompensated cirrhosis infected with hepatitis C virus (HCV) infection.

| Outcomes                        | No. of Studies | Pooled Event Rate | 95% CI       | I² (%) |
|---------------------------------|----------------|-------------------|--------------|--------|
| SVR, overall                    | 49             | 0.86              | 0.83–0.88    | 68     |
| Adverse effect                  | 13             | 0.55              | 0.31–0.77    | 96     |
| Serious adverse effect          | 12             | 0.22              | 0.13–0.36    | 93     |
| DAA discontinuation             | 11             | 0.06              | 0.04–0.08    | 52     |
| Hepatocellular carcinoma        | 14             | 0.07              | 0.05–0.09    | 72.2   |
| Mortality                       | 28             | 0.06              | 0.04–0.08    | 77.6   |
| Improvement in liver function   | 34             | 0.51              | 0.44–0.58    | 93     |
| Worsening of liver function     | 20             | 0.16              | 0.12–0.21    | 73     |
| Delisting from liver transplantation | 6     | 0.16              | 0.05–0.40    | 98.8   |

3.4. Improvement in Liver Functions and Delisting from Liver Transplantation

Since improvement in liver function is an important endpoint in patients with DC, a thorough analysis was performed in patients with decompensation only to observe the effect of DAA on improvement or deterioration of liver function. Most studies (n = 17) defined changes in liver function using MELD, while eleven used changes in the Child–Pugh class, four used both, and eight observed clinical signs such as portal hypertension. Evaluation of improvement in liver function was conducted based on 34 studies that showed a pooled event rate of 51% (95% CI: 0.44–0.58) (Table 3). Further analysis was performed using six studies to observe whether the efficacy of DAA led to delisting from liver transplantation (LT) following re-compensation from DC. The positive impact of DAA allowed 16% (n = 6, 95% CI: 0.05–0.4) of the studied patients to be removed from the LT lists. However, deterioration of liver function could not be avoided in 16% (95% CI: 0.12–0.21) of DC patients when the analysis was performed according to 20 studies with heterogeneity of I² > 70% for both outcomes (Table 3, Figure 3A–C).

In addition, the efficacy of DAA in DC was compared with that in CC patients, where DC patients showed a significantly higher rate of improvement in liver function (n = 8, OR 3.2, 95% CI: 1.29–7.95) than that of CC patients (Supplementary Figure S3A). Moreover, the deterioration of liver function was comparable between the DC and CC patients (n = 3, OR 0.8, 95% CI: 0.47–1.38) (Supplementary Figure S3B).
In addition, the efficacy of DAA in DC was compared with that in CC patients, where DC patients showed a significantly higher rate of improvement in liver function (n = 8, OR 3.2, 95% CI: 1.29–7.95) than that of CC patients (Supplementary Figure S3A). Moreover, the deterioration of liver function was comparable between the DC and CC patients (n = 3, OR 0.8, 95% CI: 0.47–1.38) (Supplementary Figure S3B).

(A) 

3.5. Efficacy and Safety of PI-based DAA in DC Patients

Since the efficacy of PI-based DAA has not been fully studied in DC patients, its safety was compared to that of non-PI-based DAAs. The PIs included in this study were glecaprevir, grazoprevir, paritaprevir, and simeprevir. The pooled SVR for 6315 PI-based DAA-treated DC patients was 85% (95% CI: 0.75–0.91), which did not differ from the non-PI-based treated group (n = 7866), with an SVR of 86% (95% CI: 0.84–0.89) (Table 2). In addition, PI did not have a significant impact on either AEs or SAEs, with pooled rates of 49% vs. 58% and 23% vs. 18% in PI- and non-PI-based treatments, respectively (Table 4). Patients treated with a PI-containing regimen (n = 2244) were more likely to be associated with the deterioration of liver function with a pooled event rate of 22% (95% CI: 0.20–0.25), while non-PI-based regimens (n = 2661) showed a pooled event rate of 14% (95% CI: 0.09–0.2). In contrast, the improvement in liver function was comparable between these two groups: 49% vs. 51% (n = 204, 95% CI: 0–1 and n =

Figure 3. Estimated event rate of (A) improvement in liver function, (B) delisting from liver transplantation, and (C) worsening in liver function of decompensated liver cirrhosis patients treated with direct-acting antiviral (DAA).
Figure 3. Estimated event rate of (A) improvement in liver function, (B) delisting from liver transplantation, and (C) worsening in liver function of decompensated liver cirrhosis patients treated with direct-acting antiviral (DAA).

3.5. Efficacy and Safety of PI-based DAA in DC Patients

Since the efficacy of PI-based DAA has not been fully studied in DC patients, its safety was compared to that of non-PI-based DAAs. The PIs included in this study were glecaprevir, grazoprevir, paritaprevir, and simeprevir.

The pooled SVR for 6315 PI-based DAA-treated DC patients was 85% (95% CI: 0.75–0.91), which did not differ from the non-PI-based treated group (n = 7866), with an SVR of 86% (95% CI: 0.84–0.89) (Table 2). In addition, PI did not have a significant impact on either AEs or SAEs, with pooled rates of 49% vs. 58% and 23% vs. 18% in PI- and non-PI-based treatments, respectively (Table 4). Patients treated with a PI-containing regimen (n = 2244) were more likely to be associated with the deterioration of liver function with a pooled event rate of 22% (95% CI: 0.20–0.25), while non-PI-based regimens (n = 2661) showed a pooled event rate of 14% (95% CI: 0.09–0.2). In contrast, the improvement in liver function was comparable between these two groups: 49% vs. 51% (n = 204, 95% CI: 0–1 and n = 3496, 95% CI: 0.42–0.59) with a similar pooled mortality rate of 5% vs. 6% (n = 690, 95% CI: 0.04–0.07 and n = 5094, 95% CI: 0.04–0.09) (Table 4).
Table 4. Summary of the estimated event rate in decompensated cirrhosis patients with chronic hepatitis C virus (HCV) infection depending on the use of protease-inhibitor-containing regimen.

| Outcomes                                  | No. of Studies | Pooled Event Rate | 95% CI       | I² (%) |
|-------------------------------------------|----------------|-------------------|--------------|--------|
| Adverse effect                            |                |                   |              |        |
| Yes                                       | 4              | 0.49              | 0.11–0.88    | 88.4   |
| No                                        | 9              | 0.58              | 0.24–0.86    | 97.1   |
| Serious adverse effect                     |                |                   |              |        |
| Yes                                       | 3              | 0.23              | 0.07–0.83    | 79.4   |
| No                                        | 9              | 0.18              | 0.09–0.33    | 77.9   |
| Worsening of liver function                |                |                   |              |        |
| Yes                                       | 4              | 0.22              | 0.20–0.25    | 0      |
| No                                        | 14             | 0.14              | 0.09–0.20    | 80.6   |
| Improvement in liver function              |                |                   |              |        |
| Yes                                       | 2              | 0.49              | 0–1.00       | 92.7   |
| No                                        | 23             | 0.51              | 0.42–0.59    | 93.2   |
| Hepatocellular carcinoma                   |                |                   |              |        |
| Yes                                       | 1              | 0.05              | 0.03–0.1     | NA     |
| No                                        | 11             | 0.07              | 0.04–0.1     | 77.8   |
| Mortality                                 |                |                   |              |        |
| Yes                                       | 5              | 0.05              | 0.04–0.07    | 0      |
| No                                        | 21             | 0.06              | 0.04–0.09    | 82.4   |

Abbreviations: NA, not applicable.

4. Discussion

The clinical impact of DAAs on DC was thoroughly assessed in the current study. The pooled SVR rate of DC (86%) is in accordance with previous major studies reporting an SVR rate of 83% in patients who received sofosbuvir–velpatasvir, a pan-genotypic DAA, 87% in patients receiving ledipasvir and sofosbuvir plus ribavirin, and 78–86% in those who received any DAA [5,9,21,24]. In comparison to that of CC, DC patients showed a lower SVR rate with an OR of 0.43. Although the pooled event rate of SVR was not as high as that of CC patients (>90%), DAA can be recommended for DC patients, as reaching SVR may lead to a better prognosis in DC patients.

The present study is the first to evaluate the pooled SVR rate and clinical events occurring in DC patients following DAA treatment. Unlike the SVR rate in the IFN era, which differed between Asian and Western countries owing to different proportions of HCV genotypes infected by patients that resulted in variable response rates [73], this was not observed in our studies. SVR was not associated with age or HCV genotype, while the presence of liver decompensation seems to be the only factor that affects the SVR rate. Based on many clinical trials, the effect of DAAs has been validated in both CHC and cirrhosis patients for all genotypes [74–76].

The occurrence of HCC and mortality are important outcomes in DC patients after HCV eradication following DAA treatment. We analyzed this important outcome and found the pooled mortality rate related to DAA and the development of HCC to be 6% and 7%, respectively, in DC patients. Furthermore, drug discontinuation following AEs was relatively low (6%) and did not lead to high mortality, as observed in the above results.
A study by Kumada et al. showed that the cumulative incidence rate of liver-related mortality confined to DC was lower in the DAA group (39.6%) than in the non-DAA group (50.6%), supporting the benefit of DAA in DC patients [33]. The large difference in survival rate between our meta-analysis and the study by Kumada et al. can be explained by different cut-off values for follow-up duration, where most of the follow-up duration in our studies was between 6 and 12 months following SVR; patients in the study by Kumada et al. were persistently followed up until death or loss. Another study by Cheung et al. showed a mortality rate of 9.9% over 15 months in DAA-treated patients, and 5.4% developed liver cancer [26]. In accordance with these results, overall DAA-related mortality and development of HCC were low in DC, which indicates that long-term clinical benefit following viral clearance can be expected. However, the effect of DAA did not lead to the same prognosis as that of CC. Since most of the studies included in our analysis had a follow-up duration of less than one year after SVR, the growth of HCCs could have been radiologically undetectable at treatment baseline rather than de novo development. Therefore, the presence of advanced liver disease at treatment initiation is the main factor predicting long-term outcomes, regardless of SVR or AEs of DAAEs [24]. Therefore, early diagnosis of HCV infection is warranted before disease progression.

Another important issue in DC is the aggravation of liver function, which affects both survival and quality of life. First, we addressed the efficacy and safety of PI-based DAA in decompensated CHC patients. Pis are metabolized by the liver, and patients with impaired liver function are subsequently exposed to elevated serum PI concentrations. Although there are limited studies including patients with decompensated liver cirrhosis in clinical trials, the real-world efficacy, and safety of PI have been reported [15,21,49]. The improvement in liver function was comparable between those treated with PI and those who did not, with a similar rate of AEs and mortality between these two groups, demonstrating that PI-based regimens can be considered for DC patients. This is an important finding because the PI-containing regimen voxilaprevir/velpatasvir/sofosbuvir is approved for pangenotypic treatment after DAA failure, which is currently indicated for CC patients only where our study may provide evidence for considering treatment in DC patients when primary treatment fails.

When the improvement in liver function was assessed in overall DC patients, we observed an improvement in 51% of these patients. Effective antiviral treatment with suppression of ongoing hepatic inflammation may inhibit long-term cirrhosis-associated complications, and achievement of SVR may lead to improvement in hepatic function, as reflected by CTP and MELD scores. The improvement in liver function was more prominent in DC patients than in CC patients, most probably owing to the improvement in ascites, hepatic encephalopathy, and liver function represented by bilirubin and international normalized ratio. This could have led to the delisting of liver transplantation in 16% of DC patients treated with DAA, which could eventually lead to a decrease in mortality. In accordance with these findings, the number of liver transplantations in patients with HCV-related DC has been reported to have rapidly decreased in the DAA era compared to that in the IFN era [58,59,64].

Our study had several limitations. First, the number of studies on PI-based DAA in DC patients was small, with inconsistent proportions of PI-based DAAAs due to the limited number of trials that included DC patients; therefore, analysis for every single PI regimen was not available. Second, the heterogeneity was moderate in the SVR rate and improvement in liver function. Several factors may have contributed to such variance, such as the study design, selective process of data, and degree of liver disease progression, which may have resulted in straying from the intended study design. Another limitation of this study is the lack of defined follow-up duration for analysis of mortality and HCC occurrence, rendering varying duration of follow-up after SVR, which cannot be adjusted by applying a cut-off for follow-up duration due to the small number of evidence in subgroup analysis. We should acknowledge that most of the evidence in this systematic review is based on observational studies that are subject to potential biases.
5. Conclusions

Despite these challenges and limitations, DAA is highly effective and well tolerated in decompensated liver cirrhosis patients, traditionally a hard-to-treat population. The PI-based DAAs appeared to be relatively safe without increasing the mortality rate compared to that of non-PI-based treated patients. However, comparative analysis with compensated LC demonstrated that the clearance of HCV in decompensated LC patients did not prevent death or HCC occurrence at a similar rate as compensated liver cirrhosis, as the underlying liver disease, liver function, and patient comorbidities are important factors. Nevertheless, the improvement in liver function was definite and more prominent in decompensated LC patients than in compensated LC patients, indicating that decompensated patients have a greater need for treatment, which eventually leads to improved overall survival. We believe that this systematic review may present the risks and benefits of DAA in decompensated patients based on the accumulated results reported by many countries where this is an area of interest in hepatology.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/jpm12091517/s1, Figure S1: Risk of bias; Figure S2: Estimated event rate of (A) sustained virologic response of DAAs, (B) development of hepatocellular carcinoma, and (C) mortality in decompensated vs. compensated liver cirrhosis patients with chronic HCV infection; Figure S3: Estimated event rate of (A) improvement in liver function and (B) worsening of liver function after DAA in decompensated vs. compensated liver cirrhosis patients treated with DAA.

Author Contributions: Conceptualization, S.Y.Y., D.A.P. and D.W.J.; methodology, D.A.P. and M.J.K.; software, J.A.; validation, S.Y.Y. and J.A.; formal analysis, S.Y.Y., D.A.P. and M.J.K.; investigation, J.A., J.-J.Y. and S.B.A.; resources, D.A.P.; data curation, S.Y.Y., D.A.P. and M.J.K.; writing—original draft preparation, S.Y.Y.; writing—review and editing, S.Y.Y. and D.W.J.; visualization, J.A., J.-J.Y. and S.B.A.; supervision, D.A.P. and D.W.J.; project administration, S.Y.Y. and J.A.; funding acquisition, S.Y.Y. All authors have read and agreed to the published version of the manuscript.

Funding: This study was funded by the National Evidence-based Healthcare Collaborating Agency (NECA; project number: NC20-001).

Institutional Review Board Statement: NECA IRB20-028.

Informed Consent Statement: Not applicable.

Data Availability Statement: Clinical trial number: PROSPERO (International Prospective Register of Systematic Reviews), CRD42021241245.

Acknowledgments: This research was supported by the Korea University Research Fund.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. WHO. Global Hepatitis Report, 2017; WHO: Geneva, Switzerland, 2017.
2. Korean Association for the Study of the Liver. 2021 Hepatitis C Factsheet; Korean Association for the Study of the Liver: Seoul, Korea, 2021.
3. McDonald, S.A.; Innes, H.A.; Aspinall, E.; Hayes, P.C.; Alavi, M.; Valerio, H.; Goldberg, D.J.; Hutchinson, S.J. Prognosis of 1169 hepatitis C chronically infected patients with decompensated cirrhosis in the predirect-acting antiviral era. J. Viral Hepat. 2017, 24, 295–303. [CrossRef]
4. Molnar, A.O.; Sood, M.M. Predicting in a predicament: Stroke and hemorrhage risk prediction in dialysis patients with atrial fibrillation. Semin. Dial. 2018, 31, 37–47. [CrossRef]
5. Curry, M.P.; O’Leary, J.G.; Bzowej, N.; Muir, A.J.; Korenblat, K.M.; Fenkel, J.M.; Reddy, K.R.; Lawitz, E.; Flamm, S.L.; Schiano, T.; et al. Sofosbuvir and velpatasvir for HCV in patients with compensated cirrhosis. N. Engl. J. Med. 2015, 373, 2618–2628. [CrossRef] [PubMed]
6. Nahon, P.; Bourcier, V.; Layese, R.; Audureau, E.; Cagnot, C.; Marcellin, P.; Guyader, D.; Fontaine, H.; Larrey, D.; De Ledinghen, V.; et al. Eradication of hepatitis c virus infection in patients with cirrhosis reduces risk of liver and non-liver complications. Gastroenterology 2017, 152, 142–156. [CrossRef] [PubMed]
7. Bachofner, J.A.; Valli, P.V.; Kroger, A.; Bergamin, I.; Kunzler, P.; Baserga, A.; Braun, D.; Seifert, B.; Moncek, A.; Fehr, J.; et al. Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis-4 score and aspartate aminotransferase-platelet ratio index. Liver Int. 2017, 37, 369–376. [CrossRef]

8. Krassenburg, L.A.P.; Maan, R.; Ramji, A.; Manns, M.P.; Cornberg, M.; Wedemeyer, H.; de Knegt, R.J.; Hansen, B.E.; Janssen, H.L.A.; de Man, R.A.; et al. Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity. J. Hepatol. 2021, 74, 1053–1063. [CrossRef]

9. Charlton, M.; Everson, G.T.; Flamm, S.L.; Kumar, P.; Landis, C.; Brown, R.S.; Fried, M.W.; Terrault, N.A.; O’Leary, J.G.; Vargas, H.E.; et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 2015, 149, 649–659. [CrossRef]

10. Lawitz, E.; Sulkowski, M.S.; Ghalib, R.; Rodriguez-Torres, M.; Younossi, Z.M.; Corregidor, A.; DeJesus, E.; Pearlman, B.; Rabinovitz, M.; Gitlin, N.; et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic hepatitis C virus genotype 1 in non-responders to pegyferr interferon and ribavirin and treatment-naive patients: The COSMOS randomised study. Lancet 2014, 384, 1756–1765. [CrossRef]

11. FDA. FDA Drug Safety Communication: FDA Warns of Serious Liver Injury Risk with Hepatitis C Treatments Viekira Pak and Technivie; FDA: Silver Spring, MD, USA, 2015.

12. Zuckerman, E.; Askhenasi, E.; Koval, Y.; Weitzman, E.; Tur-Kasp, R.; Brown, M.; Cohen, M.; Saadi, T.; Baruch, Y.; Carlebach, M.; et al. The real world Israeli experience of treating chronic hepatitis C genotype 1 patients with advanced fibrosis with parapataprevir/ritonavir/ombitasvir, dasabuvir with or without ribavirin: A large, multi-center cohort. J. Hepatol. 2016, 64, S137. [CrossRef]

13. Lawitz, E.; Poordad, F.; Guteknecht, J.A.; Yakubovitch, T.N.; Picchio, G.; Beets, G.; Van Devoorde, A.; Remoortere, P.; Jacquet, M.; Luo, D.; et al. Simeprevir, daclatasvir and sofosbuvir for hepatitis C virus-infected patients with decompensated liver disease. J. Viral. Hepat. 2017, 24, 287–294. [CrossRef]

14. Lawitz, E.; Poordad, F.; Guteknecht, J.A.; Beumont, M.; Beets, G.; Van Devoorde, A.; Remoortere, P.; Luo, D.; Vigen, L.; Eygen, V.; et al. Simeprevir, daclatasvir, and sofosbuvir for hepatitis C virus-infected patients: Long-term follow-up results from the open-label, Phase II IMPACT study. Health Sci. Rep. 2020, 3, e145. [CrossRef] [PubMed]

15. Torgersen, J.; Newcomb, C.W.; Carbonari, D.M.; Rentsch, C.T.; Park, L.S.; Mezochow, A.; Mehta, R.L.; Buchwalder, L.; Tate, J.P.; Bria, N.; et al. Protease inhibitor-based direct-acting antivirals are associated with increased risk of aminotransferase elevations but not hepatic dysfunction or decompensation. J. Hepatol. 2021, 75, 1312–1322. [CrossRef] [PubMed]

16. McIntosh, M.R.; Sibley, D.R.; Bugal, T.; Ghospe, P.; Coughlin, T.; Cohen, J.F.; Deeks, J.J.; Gatsonis, C.; Hoot, L.; et al. Preferred reporting items for a systematic review and meta-analysis of diagnostic test accuracy studies: The PRISMA-DTA statement. JAMA 2018, 319, 388–396. [CrossRef]

17. Venick, R.S.; Farmer, D.G.; Soto, J.R.; Vargas, J.; Yersiz, H.; Kaldas, F.M.; Agopian, V.G.; Hiatt, J.R.; McDiarmid, S.V.; Busuttil, R.W. One thousand pediatric liver transplants during thirty years: Lessons learned. J. Am. Coll. Surg. 2018, 226, 355–366. [CrossRef]

18. Afshar, T.; Everson, G.T.; Calleja, J.L.; McCaughan, G.W.; Bosch, J.; Brainard, D.M.; McHughan, J.G.; De-Oertel, S.; An, D.; Charlton, M.; et al. Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension. J. Viral. Hepat. 2017, 24, 823–831. [CrossRef] [PubMed]

19. Alonso, S.; Riveiro-Barciela, M.; Hernandez, J.; Rincon, D.; Rea, Y.; Llerena, S.; Gea, F.; Olveira, A.; Fernandez-Carrillo, C.; Polo, B.; et al. Effectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real-life cohort. J. Viral. Hepat. 2017, 24, 304–311. [CrossRef]

20. Backus, L.I.; Belperio, P.S.; Shahoumian, T.A.; Loomis, T.P.; Mole, L.A. Comparative effectiveness of ledipasvir/sofosbuvir plus ribavirin vs. ombitasvir/paritaprevir/ritonavir plus dasabuvir plus ribavirin in 6961 genotype 1 patients treated in routine medical practice. Aliment. Pharmacol. Ther. 2016, 44, 400–410. [CrossRef] [PubMed]

21. Berkan-Kawinska, A.; Piekaraska, A.; Janczewska, E.; Lorenc, B.; Tudrujek-Zdunek, M.; Tomasiewicz, K.; Berak, H.; Horban, A.; Zarebska-Michaluk, D.; Pabjan, P.; et al. Real-world effectiveness and safety of direct-acting antivirals in patients with cirrhosis and history of hepatic decompensation: Epi-Ter2 Study. Liver Int. 2021, 41, 1789–1801. [CrossRef]

22. Calleja, J.L.; Crespo, J.; Rincon, D.; Ruiz-Antoran, B.; Fernandez, I.; Perello, C.; Gea, F.; Lens, S.; Garcia-Samaniego, J.; Sacristan, B.; et al. Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort. J. Hepatol. 2017, 66, 1138–1148. [CrossRef]

23. Calvaruso, V.; Faroni, A. Hepatic benefits of HCV cure. J. Hepatol. 2020, 73, 1548–1556. [CrossRef]

24. Fernandez-Carrillo, C.; Lens, S.; Llop, E.; Pascasio, J.M.; Crespo, J.; Arenas, J.; Fernandez, I.; Balillas, C.; Carion, J.A.; de la Mata, M.; et al. Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: Analysis of data from the Hepa-C registry. Hepatology 2017, 65, 1810–1822. [CrossRef]

25. Chatterjee, J.G.; Konar, A.; Bhattacharya, S. Outcome of decompensated hepatitis C cirrhosis with DAA—A tertiary care experience from Kolkata. J. Gastroenterol. Hepatol. 2019, 34, 121. [CrossRef]

26. Cheung, M.C.M.; Walker, A.J.; Hudson, B.E.; Verma, S.; McLauchlan, J.; Mutimer, D.J.; Brown, A.; Gelson, W.T.H.; MacDonald, D.C.; Agarwal, K.; et al. Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. J. Hepatol. 2016, 65, 741–747. [CrossRef] [PubMed]
27. Dettering, K.; Honer Zu Siederdissen, C.; Port, K.; Solbach, P.; Sollik, L.; Kirschner, J.; Mix, C.; Cornberg, J.; Worzala, D.; Mix, H.; et al. Improvement of liver function parameters in advanced HCV-associated liver cirrhosis by IFN-free antiviral therapies. *Aliment. Pharmacol. Ther.* 2015, 42, 889–901. [CrossRef] [PubMed]

28. Garg, G.; Dixit, V.K.; Shukla, S.K.; Singh, S.K.; Sachan, S.; Tiwari, A.; Yadav, V.K.; Yadav, D.P. Impact of Direct Acting Antiviral Drugs in Treatment Naive HCV Cirrhosis on Fibrosis and Severity of Liver Disease: A Real Life Experience from a Tertiary Care Center of North India. *J. Clin. Exp. Hepatol.* 2018, 8, 241–249. [CrossRef]

29. Goel, A.; Bhargava, R.; Rai, P.; Aggarwal, R. Treatment of chronic genotype-3 hepatitis C virus infection using direct-acting antiviral agents: An Indian experience. *Indian J. Gastroenterol.* 2017, 36, 227–234. [CrossRef]

30. Gupta, S.; Rout, G.; Patel, A.H.; Mahanta, M.; Kalra, N.; Hwang, P.; Caro, L.; Robertson, M.; Charles, E.D.; et al. Elbasvir/Grazoprevir in People With Hepatitis C Genotype 1 Infection and Child-Pugh Class B Cirrhosis: The C-SALT Study. *Clin. Transl. Gastroenterol.* 2019, 10, e00007. [CrossRef]

31. Moussa, M.; Ibrahim, H.; Sakr, A. Response and safety of treatment of chronic hepatitis C by direct-acting antiviral drugs in patients with Child B-related cirrhosis. *Menoufia Med. J.* 2021, 34. [CrossRef]

32. Jacobson, I.M.; Poordad, F.; Firpi-Morell, R.; Everson, G.T.; Verna, E.C.; Bhanja, S.; Brown, R.S., Jr. Daclatasvir and sofosbuvir treatment of compensated liver disease or post-liver transplant hepatitis C virus recurrence in patients with advanced liver disease/cirrhosis in a real-world cohort. *Hepatol. Commun.* 2018, 2, 354–363. [CrossRef] [PubMed]

33. Kumada, T.; Toyoda, H.; Yasuda, S.; Tada, T.; Tanaka, J.; Chayama, K.; Johnson, P.J.; Irving, W.L. Comparison of the Prognosis of Decompensated Cirrhosis in Patients with and Without Eradication of Hepatitis C Virus. *Infect. Dis. Ther.* 2021, 10, 1001–1013. [CrossRef] [PubMed]

34. Kwo, P.; Fried, M.W.; Reddy, K.R.; Soldevila-Pico, C.; Khemichian, S.; Darling, J.; Zaman, P.J.; Napoli, A.A.; Anduze-Faris, B.; Brown, R.S., Jr. Daclatasvir and sofosbuvir treatment of compensated liver disease or post-liver transplant hepatitis C virus recurrence in patients with advanced liver disease/cirrhosis in a real-world cohort. *Hepatol. Commun.* 2018, 2, 354–363. [CrossRef] [PubMed]

35. Lens, S.; Fernandez, I.; Rodriguez-Tajes, S.; Hontangas, V.; Vergara, M.; Forne, M.; Calleja, J.L.; Diago, M.; Llaneras, J.; Llerena, S.; et al. Interferon-Free Therapy in Elderly Patients With Advanced Liver Disease. *Ann. J. Gastroenterol.* 2017, 112, 1400–1409. [CrossRef]

36. Lens, S.; Baiges, A.; Alvarado-Tapias, E.; Llop, E.; Martinez, J.; Fortea, J.I.; Ibanez-Samaniego, L.; Marino, Z.; Rodriguez-Tajes, S.; Gallego, A.; et al. Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension. *J. Hepatol.* 2020, 73, 1415–1424. [CrossRef]

37. Lim, J.K.; Liapakis, A.M.; Shiffman, M.L.; Lok, A.S.; Zeuzem, S.; Terrault, N.A.; Park, J.S.; Landis, C.S.; Hassan, M.; Gallant, J.; et al. Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis. *Clin. Gastroenterol. Hepatol.* 2018, 16, 1811–1819. [CrossRef] [PubMed]

38. Lobato, C.M.O.; Codes, L.; Silva, G.F.; Souza, A.F.M.; Coelho, H.S.M.; Pedroso, E.R.; Lima, L.; Borba, L.A.; Evangelista, A.S.; et al. Direct antiviral therapy for treatment of hepatitis C: A real-world study from Brazil. *Ann. Hepatol.* 2019, 18, 849–854. [CrossRef]

39. Maan, R.; van Tilborg, M.; Dettering, K.; Ramji, A.; van der Meer, A.J.; Wong, F.; Fung, S.; Sherman, M.; Manns, M.P.; Cornberg, M.; et al. Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis. *Clin. Gastroenterol. Hepatol.* 2016, 14, 1821–1830. [CrossRef] [PubMed]

40. Macken, L.; Gelson, W.; Priest, M.; Abouda, G.; Barclay, S.; Fraser, A.; Healy, B.; Irving, W.; Verma, S. Efficacy of direct-acting antivirals: UK real-world data from a well-characterised predominantly cirrhotic HCV cohort. *J. Med. Virol.* 2019, 91, 1979–1988. [CrossRef]

41. Mandorfer, M.; Kozbial, K.; Schwabl, P.; Freissmuth, C.; Schwarz, R.; Stern, R.; Chromy, D.; Stattermayer, A.F.; Reiberger, T.; Beinhardt, S.; et al. Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension. *J. Hepatology.* 2016, 65, 692–699. [CrossRef]

42. Mangia, A.; Lawitz, E.; Gane, E.; Conway, B.; Ruane, P.; Abergel, A.; McNabb, B.; Osinski, A.; Chen, F.; Dvory-Sobol, H.; et al. Long-term follow-up of patients with chronic HCV infection and compensated or decompensated cirrhosis following treatment with sofosbuvir-based regimens. *J. Hepatol.* 2018, 68, 567–568. [CrossRef]

43. Mazzarelli, C.; Condime, A.; Childs, K.; Carey, I.; Manini, M.A.; Suddle, A.; Dusheiko, G.; Agarwal, K.; Cannon, M.D. Efficacy and Tolerability of Direct-Acting Antivirals for Hepatitis C in Older Adults. *J. Am. Geriatr. Soc.* 2018, 66, 1339–1345. [CrossRef]

44. Papateodoridou, M.; Dalekos, G.N.; Goulis, J.; Manolakopoulos, S.; Triantos, C.; Zachou, K.; Koukoufi, A.; Kappaourikou, A.; Zetasimopoulos, K.; Tausoulas, C.; et al. Prioritization for interferon-free regimens and potential drug interactions of current direct-acting anti-hepatitis C agents in routine clinical practice. *Ann. Gastroenterol.* 2017, 30, 542–549. [CrossRef] [PubMed]

45. Pascasio, J.M.; Vinaixa, C.; Ferrer, M.T.; Colmenero, J.; Rubin, A.; Castells, L.; Manzano, M.L.; Lorente, S.; Testillano, M.; Xiol, X.; et al. Clinical outcomes of patients undergoing antiviral therapy while awaiting liver transplantation. *J. Hepatol.* 2017, 67, 1168–1176. [CrossRef] [PubMed]

46. Poordad, F.; Schiff, E.R.; Vierling, J.M.; Landis, C.; Fontana, R.J.; Yang, R.; McPhee, F.; Hughes, E.A.; Noviello, S.; Swenson, E.S. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. *Hepatology* 2016, 63, 1493–1505. [CrossRef]
54. Tmu, N.; Kumar, A.; Sharma, P.; Singla, V.; Bansal, N.; Arora, A. Results of Sofosbuvir Plus Ribavirin in Patients With Hepatitis C. *J. Viral. Hepat.* 2019, 26, 1200–1209. [CrossRef] [PubMed]
58. Belli, L.S.; Berenguer, M.; Cortesi, P.A.; Strazzabosco, M.; Rockenschaub, S.R.; Martini, S.; Morelli, C.; Donato, F.; Volpes, R.; Pageaux, G.P.; et al. Delisting of liver transplant candidates with chronic hepatitis C virus after viral eradication: A European study. *J. Hepatol.* 2016, 65, 524–531. [CrossRef] [PubMed]
59. Shiffman, M.L.; James, A.M.; Long, A.G.; Alexander, P.C. Treatment of chronic HCV with sofosbuvir and simeprevir in patients with cirrhosis and contraindications to interferon and/or ribavirin. *Am. J. Gastroenterol.* 2015, 110, 1179–1185. [CrossRef]
60. Bittermann, T.M.; Petersen, J.; Herzer, K.; Ferenci, P.; Gschwantler, M.; Wedemeyer, H.; Berg, T.; Spengler, U.; Weiland, O.; van der Valk, M.; et al. Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced/decompensated cirrhosis. *Gut* 2016, 65, 1131–1140. [CrossRef]
61. Curry, M.P.; Gane, E.; Manns, M.; McCaughan, G.; Peck-Radosavljevic, M.; Van Vlierberghe, H.; Denning, J.; Brainard, D.M.; McHutchinson, J.G.; et al. Baseline Factors Associated With Improvements in Decompensated Cirrhosis After Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection. *Hepatology* 2018, 69, 810–817. [CrossRef]
62. Bittermann, T.; Reddy, K.R. In the Era of Direct-Acting Antivirals, Liver Transplant Delisting Due to Clinical Improvement for Hepatitis C Remains Infrequent. *Clin. Gastroenterol. Hepatol.* 2021, 19, 2389–2397.e2. [CrossRef]
63. Curry, M.P.G.E.; Manns, M.; McCaughan, G.; Peck-Radosavljevic, M.; Van Vlierberghe, H.; Denning, J.; Brainard, D.M.; McHutchinson, J.G.; et al. B.A.R.C.O.S. (Brazilian Argentine Hepatitis C Collaborative Observational Study): Effectiveness and clinical outcomes of HCV treatment with daclatasvir and sofosbuvir with or without ribavirin. *J. Viral. Hepat.* 2019, 26, 1200–1209. [CrossRef] [PubMed]
68. Manolakopoulos, S.; Akriviadis, E.; Vlachogiannakos, J.; Papageorgiou, M.V.; Kapatais, A.; Oikonomopoulou, M.; Papatheodoridis, G.V. The impact of direct acting antivirals (DAAs) in patients with decompensated liver disease (DLD) due to chronic hepatitis C (CHC). heraclis-a multicenter greek real world study. Hepatology 2017, 66, 838A–839A.

69. McCaughan, G.W.; Thwaites, P.A.; Roberts, S.K.; Strasser, S.I.; Mitchell, J.; Morales, B.; Mason, S.; Gow, P.; Wigg, A.; Tallis, C.; et al. Sofosbuvir and daclatasvir therapy in patients with hepatitis C-related advanced decompensated liver disease (MELD >/= 15). Aliment. Pharmacol. Ther. 2018, 47, 401–411. [CrossRef]

70. Modi, A.A.; Nazario, H.; Trotter, J.F.; Gautam, M.; Weinstein, J.; Mantry, P.; Barnes, M.; Habib, A.; McAfee, J.; Teachenor, O.; et al. Safety and efficacy of simeprevir plus sofosbuvir with or without ribavirin in patients with decompensated genotype 1 hepatitis C cirrhosis. Liver Transpl. 2016, 22, 281–286. [CrossRef]

71. Essa, M.; Sabry, A.; Abdelsameea, E.; Tharwa, E.S.; Salama, M. Impact of new direct-acting antiviral drugs on hepatitis C virus-related decompensated liver cirrhosis. Eur. J. Gastroenterol. Hepatol. 2019, 31, 53–58. [CrossRef]

72. Sandmann, L.; Dorge, P.; Wranke, A.; Vermehren, J.; Welzel, T.M.; Berg, C.P.; Grottenthaler, J.M.; Weiss, K.H.; Langel, J.; Sterneck, M.; et al. Treatment strategies for patients with decompensated liver cirrhosis due to hepatitis C virus infection eligible for liver transplantation: Real-life data from five German transplant centers. Eur. J. Gastroenterol. Hepatol. 2019, 31, 1049–1056. [CrossRef] [PubMed]

73. Yu, M.L.; Chuang, W.L. Treatment of chronic hepatitis C in Asia: When East meets West. J. Gastroenterol. Hepatol. 2009, 24, 336–345. [CrossRef]

74. Feld, J.J.; Jacobson, I.M.; Hézode, C.; Asselah, T.; Ruane, P.J.; Gruener, N.; Abergel, A.; Mangia, A.; Lai, C.L.; Chan, H.L.; et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 Infection. N. Engl. J. Med. 2015, 373, 2599–2607. [CrossRef] [PubMed]

75. Asselah, T.; Bourgeois, S.; Pianko, S.; Zeuzem, S.; Sulkowski, M.; Foster, G.R.; Han, L.; McNally, J.; Osinusi, A.; Brainard, D.M.; et al. Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1-6 and compensated cirrhosis or advanced fibrosis. Liver Int. 2018, 38, 443–450. [CrossRef] [PubMed]

76. Zignego, A.L.; Monti, M.; Gragnani, L. Sofosbuvir/Velpatasvir for the treatment of Hepatitis C Virus infection. Acta Biomed. 2018, 89, 321–331. [CrossRef] [PubMed]